Clinical Trials

Currently Recruiting

For Muscular Dystrophy

  • Safety and feasibility of transvenous limb perfusion with normal saline in human muscular dystophy, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. [Recruiting patients with Limb-Girdle and Becker MD]

  • Assessment of magnetic resonance imaging and its potential use as an outcome measurement in Duchenne Muscular Dystrophy (DMD) patients. [Recruiting infants and children with DMD]

    • Funding: NC TraCS # 50KR71104, MDA Clinical Research Training Grant, UNC Department of Neurology Broyhill Research Award
    • Contact: Jane Fan, MD, (919) 966-8118, fanj@neurology.unc.edu
    • DP ARF ultrasound for monitoring muscle degeneration in Duchenne muscular dystrophy. [Recruiting children, ages 5, 7 or 9 with Duchenne muscular dystrophy (DMD)]

      For Myasthenia Gravis

      • A phase II, double-blind, randomized, three-way crossover, placebo-controlled, pharmacodynamic study of CK-2017357 in patients with generalized myasthenia gravis on standard therapy

      • A phase II randomized, double-blinded, controlled trial of Methotrexate versus Placebo in myasthenia gravis patients who are considered steroid dependent. [Recruiting MGFA Class II-IV MG patients]

        • Funding: UNC Department of Neurology, University of Kansas Medical Center
        • Contact: Manisha Chopra, MD, (919) 843-7857, chopram@neuology.unc.edu

      Recruitment Pending

      • Investigation of the ability of Otelixizumab to inhibit in vitro antigen-specific T cell responses from myasthenia gravis patients. [Recruiting MG patients with anti-AChR antibody]

        • Funding: GlaxoSmithKline Pharmaceuticals, Inc. MG0113510
        • Contact: Manisha Chopra, MD, (919) 843-7857, chopram@neuology.unc.edu

      Recruitment Closed

      • A randomized, double-blind, placebo-controlled, cross-over, multi-center study of eculizumab in patients with generalized myasthenia gravis (GMG) who have moderate to severe weakness despite treatments with immunosuppressants. [Recruiting refractory MGFA Class II-IV MG patients]

      • Genome wide association study in myasthenia gravis. [Recruiting caucasians with anti-AChR antibody]

        • Myasthenia Gravis Foundation Association of America
        • Contact: Manisha Chopra, MD, (919) 843-7857, chopram@neuology.unc.edu